Skip to main content
Erschienen in: Journal of Translational Medicine 1/2014

Open Access 01.05.2014 | Poster presentation

The mitochondrial master regulator gene PGC1alpha in novel sporadic melanoma cell lines: correlations with BRAF mutational status

verfasst von: Gabriella Guida, Immacolata Maida, Anna Ferretta, Tiziana Cocco, Stefania Guida, Paola Zanna, Rossella Labarile, Letizia Porcelli, Amalia Azzariti, Stefania Tommasi, Anna Albano, Sabino Strippoli, Mari C Turpin Sevilla, Raffaele Filotico, Michele Guida

Erschienen in: Journal of Translational Medicine | Sonderheft 1/2014

Einloggen, um Zugang zu erhalten

Excerpt

Metabolic reprogramming is commonly found in cancer but it is poorly understood in melanoma. Recent works [1, 2] provided new insights concerning molecular mechanisms involved in mitochondrial biogenesis of melanoma. This work aims to find possible correlations between pathways involved in the onset and progression of the disease in order to provide supporting information in this field. In particular we studied the behaviour of the mitochondrial master regulator gene PGC1alpha in novel sporadic melanoma cell lines and its relations with BRAF mutational status. …
Literatur
1.
Zurück zum Zitat Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, Wargo JA, Song JS, Fisher DE, Arany Z, Widlund HR: Oncogenic BRAF regulates oxidative metabolism via PGC1a and MITF. Cancer Cell. 2013, 23 (3): 302-315. 10.1016/j.ccr.2013.02.003.PubMedCentralCrossRefPubMed Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, Wargo JA, Song JS, Fisher DE, Arany Z, Widlund HR: Oncogenic BRAF regulates oxidative metabolism via PGC1a and MITF. Cancer Cell. 2013, 23 (3): 302-315. 10.1016/j.ccr.2013.02.003.PubMedCentralCrossRefPubMed
2.
Zurück zum Zitat Vasquez F, Lim J-H, Chim H, Bhalia K, Girnun G, Pierce K, Clish CB, Granter SR, Widlund HR, Spiegelman BM, Puigserver P: PGC1a Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress. Cancer Cell. 2013, 23 (3): 287-301. 10.1016/j.ccr.2012.11.020.CrossRef Vasquez F, Lim J-H, Chim H, Bhalia K, Girnun G, Pierce K, Clish CB, Granter SR, Widlund HR, Spiegelman BM, Puigserver P: PGC1a Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress. Cancer Cell. 2013, 23 (3): 287-301. 10.1016/j.ccr.2012.11.020.CrossRef
3.
Zurück zum Zitat Zanna P: Molecular characterization of novel melanoma cell lines. J Biol Regul Homeost Agents. 2011, 25 (2): 239-247.PubMed Zanna P: Molecular characterization of novel melanoma cell lines. J Biol Regul Homeost Agents. 2011, 25 (2): 239-247.PubMed
4.
Zurück zum Zitat Zanna P, Maida I, Grieco C, Guida S, Turbin Sevilla MC, De Summa S, Tommasi S, Vena GA, Filotico R, Guida G: Three novel human sporadic melanoma cell lines: signaling pathways controlled by MC1R, BRAF and ßcatenin. J Biol Regul Homeost Agents. 2013, 27 (1): 131-141.PubMed Zanna P, Maida I, Grieco C, Guida S, Turbin Sevilla MC, De Summa S, Tommasi S, Vena GA, Filotico R, Guida G: Three novel human sporadic melanoma cell lines: signaling pathways controlled by MC1R, BRAF and ßcatenin. J Biol Regul Homeost Agents. 2013, 27 (1): 131-141.PubMed
Metadaten
Titel
The mitochondrial master regulator gene PGC1alpha in novel sporadic melanoma cell lines: correlations with BRAF mutational status
verfasst von
Gabriella Guida
Immacolata Maida
Anna Ferretta
Tiziana Cocco
Stefania Guida
Paola Zanna
Rossella Labarile
Letizia Porcelli
Amalia Azzariti
Stefania Tommasi
Anna Albano
Sabino Strippoli
Mari C Turpin Sevilla
Raffaele Filotico
Michele Guida
Publikationsdatum
01.05.2014
Verlag
BioMed Central
Erschienen in
Journal of Translational Medicine / Ausgabe Sonderheft 1/2014
Elektronische ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-12-S1-P9

Weitere Artikel der Sonderheft 1/2014

Journal of Translational Medicine 1/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.